Combined Ovarian Tissue and Oocyte Cryopreservation for Fertility
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov registered observational study NCT07546123 will compare combined ovarian tissue cryopreservation with oocyte cryopreservation against oocyte cryopreservation alone in oncological patients undergoing gonadotoxic treatments. The study will collect data from two groups of patients assigned based on their planned gonadotoxic therapy and available time before treatment initiation. The primary endpoints are the number of oocytes retrieved per ovarian stimulation cycle and the oocyte retrieval rate between the two groups.
“Combining ovarian tissue cryopreservation followed by oocyte cryopreservation may maximize fertility preservation by safeguarding more follicles and ensuring availability of mature oocytes.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
NIH ClinicalTrials.gov registered an observational study comparing combined ovarian tissue cryopreservation followed by oocyte cryopreservation against oocyte cryopreservation alone for fertility preservation in oncological patients. Patients will be assigned to treatment groups based on their planned gonadotoxic therapy and available time before treatment initiation. The study will compare oocytes retrieved per stimulation cycle and oocyte retrieval rates between the two groups.
Healthcare providers and clinical investigators involved in fertility preservation services for cancer patients may benefit from awareness of this comparative data collection, which may inform clinical practice and patient counseling regarding cryopreservation options.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone
Observational NCT07546123 Kind: OBSERVATIONAL Apr 22, 2026
Abstract
Fertility preservation is a crucial aspect of care for oncological patients undergoing gonadotoxic treatments such as chemotherapy, radiotherapy, or surgery, which can significantly reduce ovarian reserve and cause infertility or premature menopause. Among available techniques, oocyte cryopreservation is well-established with high survival rates but requires controlled ovarian stimulation and may not be suitable for prepubertal patients or those needing urgent cancer therapy. Ovarian tissue cryopreservation offers advantages by preserving a larger number of primordial follicles, can be performed anytime in the menstrual cycle regardless of age, and also helps restore ovarian endocrine function.
Combining ovarian tissue cryopreservation followed by oocyte cryopreservation may maximize fertility preservation by safeguarding more follicles and ensuring availability of mature oocytes.
This study will collect data from two patient groups:
Group 1: patients undergoing ovarian tissue cryopreservation followed by oocyte cryopreservation (combined treatment)
Group 2: patients undergoing oocyte cryopreservation alone.
Group assignment is based on planned gonadotoxic therapy and available time before treatment initiation, according to clinical practice.
The study aims to compare the number of oocytes retrieved per ovarian stimulation cycle between the two groups, along with the oocyte retrieval rate (number of oocytes retrieved/number of aspirated follicles), number of mature o...
Conditions: Oncological Disease, Fertility Preservation
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.